Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946862/
https://www.ncbi.nlm.nih.gov/pubmed/20335368
http://dx.doi.org/10.1093/annonc/mdq077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946862/
https://www.ncbi.nlm.nih.gov/pubmed/20335368
http://dx.doi.org/10.1093/annonc/mdq077

Ejemplares similares